YB1-mRNA / HKND YB1 Pharma - LARVOL DELTA

YB-1 is involved in drug resistance and poor patient prognosis in thoracic cancers (EACR 2026) - "The expression of YB-1 mRNA and protein was evaluated in cisplatin-sensitive parental SCLC cell lines and their corresponding acquired chemoresistant clones using qPCR and Western blot analysis, to determine potential differences associated with cisplatin resistance.Result and YB-1 was overexpressed in PM cells, and YB-1 knockdown enhanced sensitivity to cisplatin treatment. Our findings indicate that YB-1 may contribute to chemotherapy resistance in thoracic malignancies primarily through stress-induced extracellular secretion rather than accumulation of intracellular protein. Circulating exYB-1 may therefore represent a clinically accessible biomarker reflecting treatment response and adverse prognosis in PM patients. Ongoing investigations in SCLC models aim to further elucidate the role of exYB-1 in acquired chemoresistance."

Clinical • Lung Cancer • Malignant Pleural Mesothelioma • Mesothelioma • Oncology • Pleural Mesothelioma • Small Cell Lung Cancer • Solid Tumor • Thoracic Cancer • YBX1

CAF-expressed YB-1 is required for stimulation of mesothelioma growth (EACR 2026) - "Recent studies have shown that YB-1 overexpression in PM cells contributes to growth, migration, cisplatin resistance, and immune evasion...Targeting YB-1 with siRNA achieved a potent reduction of YB-1 mRNA and protein levels in Meso-CAFs and resulted in decreased viability and migration capacity... YB-1 has previously been shown to drive growth and migration in different types of cancer cells, including those of PM. In the current study, we show for the first time that YB-1 is also critically involved in the growth and migration of CAFs and, moreover, its expression in CAFs is required for their stimulation of tumor growth. Effects of YB-1 inhibition on cancer cells and the TME could, therefore, both contribute to therapeutic efficacy."

Malignant Pleural Mesothelioma • Mesothelioma • Pleural Mesothelioma • Solid Tumor • CTGF • YBX1

Analysis of YB-1 in lung squamous cell cancer tissue and cell models: gene dose, expression and inhibitor response (EACR 2026) - "These data were compared to YB-1 mRNA level and protein expression...Entinostat also resulted in strong growth reduction (IC50 0.7 – 4.1 µM), while LJH685 had only a moderate effect (IC50 7.1 – 44.3 µM). The current study suggests that YB-1 is a growth driver and potential therapy target in SCC. The current study suggests that YB-1 is a growth driver and potential therapy target in SCC. Both, inhibitor treatment and YB-1 knockdown resulted in reduced cell growth. While our data show that YB-1 gene amplification occurs in a subset of SCC, YB-1 overexpression and therapeutic effects of YB-1 inhibition may not be limited to cases with YB-1 gene amplification."

Breast Cancer • Lung Cancer • Malignant Pleural Mesothelioma • Mesothelioma • Non Small Cell Lung Cancer • Oncology • Osteosarcoma • Pleural Mesothelioma • Sarcoma • Solid Tumor • Squamous Cell Carcinoma • YBX1

YBX1 Expression Marks Proliferative Tumour States with Context-Dependent Genomic Instability: A Pan-Cancer Analysis. (PubMed, Int J Mol Sci) - "Here, we performed an integrative pan-cancer analysis across 53 independent datasets spanning 33 tumour types, incorporating transcriptomic (YBX1 mRNA), proteomic (RPPA), genomic, and clinical data...Elevated YB-1 protein levels were also associated with advanced disease stage and poorer survival outcomes and demonstrated a similar, although non-significant, directional trend with histologic grade. Collectively, these findings demonstrate that elevated YBX1 expression marks proliferative and clinically aggressive tumour states within which genomic instability-related features arise in a context-dependent manner, providing a clarified pan-cancer framework for interpreting YB-1-associated tumour biology."

Journal • Pan tumor • Tumor mutational burden • Oncology • HRD • TMB • YBX1

Harnessing NOPE: A key oncofetal protein driving β-catenin signaling through peptidic antigen receptor macrophages in hepatocellular carcinoma (AACR 2026) - "In MHCC-97L cells, NOPE overexpression enhanced T-IC features, including self-renewal, tumorigenicity, cell invasiveness, expression of liver T-IC markers, and resistance to lenvatinib treatment...The NOPE/PABPC1 complex regulates cell state and drug resistance by directly affecting the β-catenin signaling pathway, potentially through its impact on YB-1 mRNA stability. We identified NOPE as a functional oncofetal protein that promotes liver cancer stemness by activating the β-catenin signaling pathway, which can be targeted by a novel pCAR-Ms approach."

Embryonal Tumor • Hepatocellular Cancer • Liver Cancer • Oncology • Solid Tumor • GPC3 • PABPC1

Y box binding protein 1 mediated modulation of chromosomal instability in cancer (LCC 2026) - "Our pan-cancer dataset analysis revealed a strong association between high YB-1 mRNA expression, increased genomic instability, and reduced disease-free survival. To explore this, we engineered H1299 lung cancer cells with tetracycline-inducible YB-1 expression...We are currently evaluating the functional consequences of prolonged YB-1 overexpression. Collectively, our data identifies, for the first time, a direct mechanistic link between YB-1 overexpression and CIN, establishing YB-1 as a key driver of tumour evolution and a promising therapeutic target."

Lung Cancer • Oncology • Solid Tumor • YBX1

Immunohistochemical analysis of YB-1 expression in the developing mouse eye. (PubMed, Eur J Histochem) - "YB-1 mRNA could be detected by RT-PCR and sequencing the PCR product in retinal tissue of adult mice...Expression of the YB-1 protein was detected in all retinal cells, as well as in the corneal and lens epithelial cells, throughout all stages of eye development examined. These findings suggest that YB-1 could have a significant role in the eye, potentially related to development and differentiation."

Journal • Preclinical • Oncology

Autoregulation of YB-1 Synthesis in Cells. (PubMed, Biochemistry (Mosc)) - "Experiments with reporter constructs showed that both UTRs of the YB-1 mRNA are involved in autoregulation, thus resolving the contradiction in the literature. These results highlight a sophisticated mechanism for controlling YB-1 levels, which requires both 5' and 3' UTRs of the YB-1 mRNA, and confirm their role in fine-tuning YB-1 synthesis."

Journal • YBX1

Targeting YBX1: A novel therapeutic strategy for gastric cancer through regulation of cellular senescence and mTOR signaling. (PubMed, Tissue Cell) - "YBX1 mRNA and protein levels were significantly higher in GC tissues than in adjacent normal tissues (P < 0.001), and high expression was associated with reduced overall survival (P < 0.05)...Thus, this study underscores YBX1 as a pivotal regulator of GC cell proliferation, senescence, and survival, offering a promising avenue for targeted therapies. By leveraging YBX1 inhibition, this work lays a foundation for developing precision medicine approaches in GC treatment."

Journal • Gastric Cancer • Oncology • Solid Tumor • EIF4EBP1 • YBX1

Oncolytic virotherapy provides a potent therapy option for squamous bladder cancer. (PubMed, Sci Rep) - "Increased YB-1-mRNA expression was detected in basal/squamous subtype in TCGA BLCA cohort compared to urothelial and luminal BLCA and correlated with patient outcomes...In a novel in ovo xenograft model, XVir-N-31 impaired growth of xenografts of patient-derived ex vivo cell lines (p-SCC, p-UC) with growth suppression rates of 39-49%. We provide preclinical evidence ex vivo and in ovo for high efficacy of XVir-N-31 based oncolytic virotherapy as novel SCC therapy."

Journal • Bladder Cancer • Genito-urinary Cancer • Infectious Disease • Oncology • Solid Tumor • Squamous Cell Carcinoma • Urothelial Cancer • YBX1

Y-box binding protein 1/cyclin A1 axis specifically promotes cell cycle progression at G2/M phase in ovarian cancer. (PubMed, Sci Rep) - "YBX1 mRNA levels were significantly correlated with cyclin A1 mRNA levels in patients with high-grade serous carcinoma. Augmented YBX1 expression plays a key role in tumor growth promotion in ovarian cancer in its close association with cyclin A1."

Journal • Oncology • Ovarian Cancer • Solid Tumor • CCNA1 • YBX1